In last trading session, AbCellera Biologics Inc. (NASDAQ:ABCL) saw 2.12 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $10.86 trading at -$0.81 or -6.94% at ring of the bell on the day assigns it a market valuation of $3.13B. That closing price of ABCL’s stock is at a discount of -408.47% from its 52-week high price of $55.22 and is indicating a discount of -1.38% from its 52-week low price of $11.01. Taking a look at company’s average trading volume of 1.81 million if we extend that period to 3-months.
For AbCellera Biologics Inc. (ABCL), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.70. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0.18 in the current quarter.
AbCellera Biologics Inc. (NASDAQ:ABCL) trade information
Upright in the red during last session for losing -6.94%, in the last five days ABCL remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $10.86 price level, adding 13.74% to its value on the day. AbCellera Biologics Inc.’s shares saw a change of -24.06% in year-to-date performance and have moved -10.17% in past 5-day. AbCellera Biologics Inc. (NASDAQ:ABCL) showed a performance of -17.48% in past 30-days.
Wall Street analysts have assigned a consensus price target of $38.88 to the stock, which implies a rise of 72.07% to its current value. Analysts have been projecting $25.00 as a low price target for the stock while placing it at a high target of $49.00. It follows that stock’s current price would drop -351.2% in reaching the projected high whereas dropping to the targeted low would mean a loss of -130.2% for stock’s current value.
AbCellera Biologics Inc. (ABCL) estimates and forecasts
Statistics highlight that AbCellera Biologics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -35.85% of value to its shares in past 6 months, showing an annual growth rate of 13.33% while that of industry is 7.90. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -59.10% in the current quarter and calculating -78.40% decrease in the next quarter. This year revenue growth is estimated to rise 51.40% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $120.31 million for the same. And 2 analysts are in estimates of company making revenue of $76.9 million in the next quarter that will end on Mar 2022. Company posted $207.91 million and $202.74 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -42.10% while estimating it to be -62.10% for the next quarter.
In 2022, company’s earnings growth rate is likely to be around 11.10% while estimates for its earnings growth in next 5 years are of 10.00%.
AbCellera Biologics Inc. is more likely to be releasing its next quarterly report between March 28 and April 01 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
AbCellera Biologics Inc. (NASDAQ:ABCL)’s Major holders
Insiders are in possession of 30.25% of company’s total shares while institution are holding 43.63 percent of that, with stock having share float percentage of 62.56%. Investors also watch the number of corporate investors in a company very closely, which is 43.63% institutions for AbCellera Biologics Inc. that are currently holding shares of the company. Capital World Investors is the top institutional holder at ABCL for having 19.82 million shares of worth $397.22 million. And as of Sep 29, 2021, it was holding 7.04% of the company’s outstanding shares.
The second largest institutional holder is Allianz Asset Management GmbH, which was holding about 11.86 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 4.21% of outstanding shares, having a total worth of $237.65 million.
On the other hand, Smallcap World Fund and Europacific Growth Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 6.33 million shares of worth $126.95 million or 2.25% of the total outstanding shares. The later fund manager was in possession of 5.41 million shares on Sep 29, 2021, making its stake of worth around $108.39 million in the company or a holder of 1.92% of company’s stock.